Patients treated with subcutaneous TREMFYAachieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO study Clinical and endoscopic outcomes were demonstrated across both biologic-naïve and biologic-refractory sub- groups TREMFYA Â is the only IL-23 inhibitor with a fully subcutaneous regimen, following recent FDA approval of SC induction in adults with ulcerative colitis , /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today anno ...

When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue. With increased volume and demand, suppliers also receive better deals, which significantly lower costs, among other benefits. Ultimately, a price discou ...

A mercury-containing preservative that is used in some vaccines has not been used in childhood vaccines since 2001, according to the Despite his concerns about childhood vaccines, Hill would not support new restrictions on them while more research is conducted. "If there are people that want it, I think it should be available to them," said Hill, a supervisor at a nuclear power plant. "While you're studying, let be available." Hill is one of 20 Americans who voted for President Donald Still, each of thes ...

Key Takeaways J&J projects stronger Innovative Medicine sales in H2 despite Stelara's LOE.Higher demand for Darzalex, Tremfya, and Erleada likely supported segment growth in Q3.Stelara biosimilars and IRA's Part D redesign continue to put pressure on J&J's drug sales.Johnson & Johnson (JNJ) , through its Innovative Medicine division, markets several blockbuster drugs across diverse therapeutic areas, including neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension (PH), an ...

Market Performance - The U.S. stock market showed strong performance last week, with major indices like the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average increasing by 0.82%, 0.84%, and 0.96% respectively [1] - Investor optimism was fueled by advancements in Artificial Intelligence and expectations for further interest rate cuts by the Federal Reserve, despite a partial government shutdown creating uncertainties [1] Consumer Confidence and Labor Market - The Conference Board's Consumer Confidence Index for September dropped by 3.6 points to 94.2, marking its lowest level since April, attributed to inflation and a weakening job market [2] - Job openings increased slightly by 19,000 to 7.227 million in August, while hiring decreased by 114,000 to 5.126 million according to the Job Openings and Labor Turnover Survey [2] Zacks Research Performance - Amneal Pharmaceuticals saw a stock increase of 29.9% since its Zacks Rank upgrade on July 25, outperforming the S&P 500's 5.5% increase [4][7] - Leidos Holdings experienced a 19.8% return following a Zacks Rank upgrade on July 28, also surpassing the S&P 500's 5.1% increase [5][7] - A hypothetical portfolio of Zacks Rank 1 stocks returned +8.64% in 2025 through September 1, compared to +7.60% for the S&P 500 index [5] Focus List and Model Portfolios - The Zacks Focus List portfolio returned 13.74% in 2025 through August 31, outperforming the S&P 500 index's 10.79% [12] - Intellia Therapeutics gained 85.9% and Shopify returned 38.3% over the past 12 weeks, significantly outperforming the S&P 500's 7% increase during the same period [11] Earnings Certain Admiral Portfolio (ECAP) - The ECAP returned +0.20% in Q2 2025, underperforming the S&P 500 index's +10.94% gain [16] - The portfolio aims to minimize capital loss by holding shares of companies with a proven track record of earnings stability over 20+ years [17] Earnings Certain Dividend Portfolio (ECDP) - Johnson & Johnson returned 20.9% and Home Depot increased by 6.3% over the past 12 weeks, benefiting from investor preference for quality dividend stocks amid market volatility [19] - The ECDP returned -3.17% in Q2 2025, compared to the S&P 500 index's +10.94% gain [20] Top 10 Stocks Performance - Goldman Sachs, part of the Zacks Top 10 Stocks for 2025, increased by 38% year-to-date, outperforming the S&P 500 index's 14.2% increase [22] - The Top 10 portfolio has produced a cumulative return of +2,369.7% since 2012, significantly outperforming the S&P 500 index's 522.5% [24]

How Focusing On Meeting Deadlines Can Cost More Than Missing ThemgettyIt might sound counterintuitive to say that deadlines cost more than missing them, but the reality is there is a hidden danger in treating deadlines as sacred. There is an opportunity cost of finishing on time without asking enough questions. When leaders push projects forward no matter what, they often silence curiosity, discourage people from raising concerns, and miss the chance to slow down in ways that could prevent disaster. There a ...

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer put under the microscope. Cramer recalled his discussion with the company’s CEO, and commented: “What else might work? Last Friday on the show, we had Joaquin Duato. He’s the CEO of Johnson & Johnson, and he told a remarkable story about game-changing cancer drugs and medical devices, especially their excellent cardio products. Now, I’ve been worried about the talc lawsuits that they have, but I believe the risk from the asbestos and the baby po ...

Welcome back to Market on Close. Shares of Johnson and Johnson hit a new all-time high today after Wells Fargo upgraded the stock to overweight from equal weight and raised its price target to $212 from $170. The firm says it sees potential upside to J&J's pharma business and lowered tariff and pricing risks.Wells Fargo said the stock's valuation presents an attractive entry point right now. So now it's time for Options Corner. Joining us is Rick Dukat, our lead market technician here on Schwab Network to t ...

U.S. stock market surged to record highs on Friday. The Dow rose 366 points to 46,238, the S&P 500 gained 0.4% to 6,823, and the The gains put the indexes on track for a positive week. The S&P 500 and Dow are up more than 1% week to date. The Nasdaq has risen nearly 2%, and the Russell 2000 is up 2.4%. Investors remain confident that the government shutdown, now in its third day, will be short-lived. Historically, shutdowns have not significantly affected market momentum. The shutdown has paused economic r ...

Investors with a lot of money to spend have taken a bearish stance on Johnson & Johnson (NYSE:JNJ).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JNJ, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner sp ...